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Background: Various types of hyperkeratotic lesions can be observed in patients with psori-
asis treated with PUVA. Clinically it can be difficult to classify them and to differentiate be-
nign from malignant hyperkeratotic lesions. Recently, we introduced the term PUVA kera-
tosis, which we regard äs a distinct entity.
Objective: The purpose of the study was to describe in more detail the clinical and
histopathologic features of PUVA keratoses and to investigate a possible relation with non-
melanoma skin cancer.
Methode: A group of 13 psoriasis patients with PUVA keratoses was studied and compared
with 247 psoriasis patients without these keratoses, who had also received long-term therapy
with PUVA.
Results: The presence of PUVA keratoses was associated with an increased risk of nonmel-
anoma skin cancer. The estimated relative risk for skin cancer in patients with PUVA kera-
toses, adjusted for age, sex, and UVA dose, äs compared with psoriasis patients without these
keratoses, who had also received long-term PUVA. treatment, was 6.5 (95% confidence in-
terval, 1.3 to 32.1). Squamous cell carcinomas contributed the most to this increased risk.
Conclusion: PUVA keratoses are associated with an increased risk of nonmelanoma skin
cancer. Therefore careful clinical follow-up of psoriasis patients with PUVA keratoses is nec-
essary, and cessation of PUVA treatment should be considered.
(J AM ACAD DERMATOL 1993;28:412-7.)
Various types of benign hyperkeratotic lesions
can be observed in patients with psoriasis.1"4 Re-
cently, we described PUVA keratosis in a long-term
follow-up study of 260 patients with psoriasis, who
were treated with 8-methoxypsoralen and UVA ra-
diation (PUVA) between 1975 and 1988.5 This
keratosis has been recognized for years by PUVA
investigators, but a thorough study has not been
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done. A PUVA keratosis was defined äs a raised
papule with a broad base and a diameter of several
millimeters to about l cm. The top of the lesion is
hyperkeratotic and scaly and has a warty appear-
ance (Figs. l and 2).
In the present study, we describe in more detail
the clinical and histopathologic features of PUVA
keratosis. In addition, the prevalence of nonmela-
noma skin cancer in patients with PUVA keratoses
was compared with the prevalence of nonmelanoma
skin cancer in a large group of PUVA-treated pso-
riasis patients without these keratoses and the rela-
tive risk for development of nonmelanoma skin can-
cer was assessed in the patient group with PUVA
keratoses.
PATIENTS AND METHODS
Between 1975 and 1988, 334 patients with psoriasis
were treated with oral photochemotherapy (PUVA) in
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Fig. 1. Four typical PUVA keratoses (arrows) and numerous PUVA freckles are present
on the back.
Fig. 2. Detail of PUVA keratosis.
the Leiden University Hospital. Seventy-four patients did
not participate in the follow-up study for reasons men-
tioned in our previous article.5 Therefore a total of 260
patients were examined in 1987. Before 1987, the pres-
ence of benign skin tumors was not documented. Of these
260 patients, 13 patients with PUVA keratoses were se-
lected for further characterization.
All patients had been treated with a Standard PUVA
regimen. 8-Methoxypsoralen (0.5 to 0.6 mg/kg of body
weight) was taken orally 2 hours before treatment. The
initial UVA dose of each patient depended on skin sensi-
tivity to UVA6 and ranged from 0.3 to l .0 joule/cm2. The
Clearing treatment consisted of a three-times-a-week
schedu'e, in which the dose was elevated by 10%, 20%, or
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Table I. Baseline characteristics of the patients with and without PUVA keratoses
No. of patients
Male/female ratio
Skin type
II
III
IV
V
Duration of follow-up (yr)
(mean ± SD)
Age at the statt of PUVA
(yr) (mean ± SD)
Age at physical
examination (yr)
(mean ± SD)
No. of treatments
(mean ± SD)
DoseofUVA(J/cm2)
(mean ± SD)
No. of patients with
NMSC (%)
Total No. ofNMSC
No. ofSCCs
No. of BCCs
Patients with
PUVA keratoses
13
12:1
2
10
1
—
10.6 ± 1.7
52.7 ± 12.6
63.9 ± 11.4
179 + 59
1693 ± 801
4 (30.8)
10
7
3
Patients without
PUVA keratoses
247
154:93
14
203
21
9
8.6 ± 2.8
42.5 ± 4.6
51.4 ± 14.4
98 ±58
776 ± 713
7 (2.8)
27
6
21
Differences between
the groups (95 % CI)
2.0 (0.45;3.6)
10.2(2.1;18.3)
12.4(4.4;20.4)
81.0(48.5;! 14.0)
917(516;1319)
BCC, Basal cell carcinoma; CI, confidence interval; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma; SD, Standard deviation.
30% every other Session. Immediately after Clearing, a
maintenance regimen was followed, during which the
frequency was gradually reduced to one treatment every
2 or 3 weeks. The last administered UVA dose was kept
unaltered, ranging from 2 to 15 joules/cm2. If the psori-
asis relapsed, the treatment frequency was temporarily
increased.
The patients with and without PUVA keratoses were
compared äs to age, sex, skin type, previous use of arseni-
cals, methotrexate, or etretinate, exposure to x-rays or
UVB, total UVA dosage, and the occurrence of nonmel-
anoma skin cancer. Skin types were defined according to
Johnson and Lookingbill.7 It was determined whether
PUVA keratoses were localized in sun-exposed areas.
Skin biopsies of representative lesions were performed
in 10 patients. Routinely stained (hematoxylin and eosin;
Verhoeff-van Gieson) sections of PUVA keratoses were
examined. The presence of orthokeratosis, parakeratosis,
acanthosis, papillomatosis, apoptosis, atypical epidermal
cells, inflammatory infiltrate, and elastosis was recorded.
To compare the prevalence of nonmelanoma skin can-
cer in the group of psoriasis patients with PUVA kera-
toses and the group without these keratoses, the chi-
square test was applied. Values of p less than 0.05 were
considered to indicate statistical significance. Differences
between the groups in mean age, mean number of treat-
ments, and mean UVA dose were calculated by the un-
paired two-tailed Student / test. Results were expressed
äs means ± Standard deviation.
The crude and the adjusted odds ratios with 95% con-
fidence interval were calculated for estimation of the rel-
ative risk of nonmelanoma skin cancer for psoriasis
patients with PUVA keratoses, compared with patients
without these keratoses. This was done by maximum
likelihood estimation in a logistic model (Egret, Statistics
and Epidemiology Research Corporation, Seattle,
Wash.). The crude odds ratio was adjusted for the UVA
dose and age and sex of the patient. The same method was
applied to assess the relative risk of PUVA keratoses in
relation to the UVA dose and age and sex of the patient.
For statistical analysis the number of person-years at
risk was computed by the Kaplan-Meier analysis. The
number of person-years was calculated between arbi-
trarily chosen opening and ciosing dates. As the opening
date for this calculation the date of the first PUVA treat-
ment was used. As ciosing date we used the date of diag-
nosis of the first skin cancer or theend of the study on Dec.
31, 1987.
RESULTS
Clinical data
The mean age of all patients at the start of PUVA
treatment was 43.4 years (ränge 20 to 86 years) and
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Table II. Estimated relative risk (odds ratio) of
PUVA keratoses in relation to the dose of UVA
and age and sex of the patient
Crude odds
ratio (95% CI)
Adjusted odds
ratio (95 % CI)*
UVA dose (J/cm2)
600-1199 vs 0-599 8.8 (0.90;211.8) 9.6(1.0;91.3)
>1200vs 0-599 17.9(2.2;391.1) 16.2(1.9;137.0)
Age (yr)
1.4(0.12;35.5) 1.0 (0.10; 10.5)
7.7(0.94;166.3) 5.8 (0.67;49.7)
40-59 vs 20-39
>60 vs 20-39
Sex
Male vs female 7.1 (0.97;100.0) 5.8 (0.71;47.5)
CI, Confidence interval.
*Odds ratio with 95% CI, calculated with a logistic regression model,
adjusted for the dose of UVA, age at physical examination, and sex of
the patient.
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Fig. 3. Cumulative UVA dose in patients with and
without PUVA keratoses (mean ± SD).
at physical examination 52.1 years (ränge 20 to 84
years). A total of 18 PUVA keratoses was observed
in 13 patients. PUVA keratoses were predominantly
observed in men (male/female ratio = 12:1). One
patient had had a basal cell carcinoma (BCC), and
one patient was treated earlier with methotrexate.
None of the patients had used etretinate or had been
treated with UVB or x-rays. The mean individual
cumulative UVA dose of the patients in whom
PUVA keratoses developed was 1693 ± SOljoules/
cm2. The mean period between the start of PUVA
therapy and the diagnosis of PUVA keratosis was
9.1 ± 2.3 years. Two patients had skin type II, 10
patients had skin type III, and l patient had skin type
IV. The localization of the PUVA keratoses on
sun-exposed versus nonexposed areas of the skin was
7:11. They were primarily observed on the trunk
and thighs. The PUVA keratoses were in general
detected later than the cutaneous malignancies.
Most PUVA keratoses were recorded for the first
time in 1987, when the PUVA-treated patients
were screened systematically for benign skin
tumors.
In Table I a comparison is made between the
group with PUVA keratoses and the group without
these keratoses. The mean cumulative dose of UVA
in the group with PUVA keratoses was significantly
higher than that in the group without PUVA kera-
toses (Fig. 3). The mean difference with 95% confi-
dence interval was 917 joules/cm2 (516 to 1319
joules/cm2). The difference between the mean ages
at the start of PUVA treatment of the two groups
was also statistically significant: 10.2 years (2.1 to
18.3 years). The crude odds ratios for the develop-
ment of PUVA keratoses and the odds ratios ad-
justed for the UVA dose and age and sex of the pa-
tient are depicted in Table II.
Until the ciosing date of our study,5 in 4 of the 13
patients with PUVA keratoses a total of 10 malig-
nant skin tumors (7 squamous cell carcinomas
[SCCs] and 3 BCCs were found. In 75% of cases, the
SCCs were graded äs highly düferentiated. Six
SCCs and one BCC were localized on non-sun-ex-
posed areas of the skin. In 7 of the 247 PUVA-
treated psoriasis patients without PUVA keratoses,
27 skin carcinomas were diagnosed (6 SCCs and 21
BCCs). The difference between the two groups is
highly significant (p < 0.0001). The crude odds ra-
tio with 95% confidence interval to develop nonmel-
anoma skin cancer in the psoriasis patient group
with,PUVA keratoses, compared with the group
without these keratoses, was 15.2 (3.8 to 61.6). Ad-
justment of this odds ratio for the UVA dose and age
and sex of the patient resulted in an estimated rel-
ative risk of 6.5 (1.3 to 32.1).
Five years after the start of PUVA treatment the
cumulative incidence of skin cancer in the patients
with PUVA keratoses was 15% (95% confidence in-
terval, 4% to 49%) and in the patients without
PUVA keratoses 2% (95% confidence interval, 1%
to 5%). Eight years after the start of PUVA treat-
ment the incidence of skin cancer in the PUVA
keratoses group had increased to 31% (95% confi-
dence interval, 13% to 63%) and to 4% (95% confi-
dence interval, 2% to 7%) in the group without
PUVA keratoses.
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Table III. Histopathologic features of PUVA keratosis in 10 patients
Histopathologic features
Patient No.
1
Hyperkeratosis ++
Parakeratosis +
Acanthosis +
2 3 4 5
+ + + + + + -
+ + + + + + -
+ ++ ++ ++
S 7 8 9 10
t- ± ++ + ++
l- + ++ + +
Acantholysis — —
Papillomatosis + —
Apoptosis - +
Atypia + ±
Mitosis + +
Infiltrate ± +
Lymphocytic Infiltration of basal layers — ±
of the epidermis
Elastosis - —
—, Absent; ±, slight; +, moderate; ++, prominent.
Histopathologic features
The frequencies of the observed histopathologic
features of the PUVA keratoses are summarized in
Table III. The punch biopsy specimens revealed an
epidermis with a variable degree of acanthosis,
orthokeratosis, focal parakeratosis, and some apop-
totic cells. In half of the specimens, papillomatosis
was observed. One lesion showed focal acantholysis.
In the papillary dermis a mild perivascular, predom-
inantly lymphocytic infiltrate, slightly invading the
epidermis, was seen in half the specimens. Only mild
atypia of keratinocytes was found in 50% of the
cases, represented by minor variations in size and
shape of cells and by minimal hyperplasia and hy-
perchromasia of the nuclei. Neither viral changes
nor typical features of psoriasis were observed (Figs.
4 and 5). In only one PUVA keratosis on the check,
was elastosis observed.
DISCUSSION
PUVA keratoses were localized on non-sun-ex-
posed skin (i.e., the trunk and thighs) in 11 of 18
cases, suggesting a primary relationship between the
development of these lesions and PUVA treatment.
In the clinical differential diagnosis psoriasis vul-
garis, verruca vulgaris, hyperkeratotic papilloma,
seborrheic keratosis, bowenoid or hypertrophic type
of solar keratosis, lichenoid keratosis, tar keratosis,
arsenical keratosis, and SCC should be considered.
Neither arsenic nor x-radiation were etiologic agents
in the development of PUVA keratoses because no
patient had been exposed to them. Three patients
had been treated with coal tar before they started
PUVA therapy, suggesting that tar can be consid-
ered äs a causal factor. Gotz2 has described 92 cases
of tar keratoses. However, none of our patients
showed keratoses before initiation of PUVA ther-
apy. In addition, tar keratoses have in general a di-
stal location (90% hands and feet) in contrast with
PUVA keratoses. PUVA keratoses differ from solar
keratoses in that the latter appear in areas of actinic
damage and are histopathologically characterized
by more obvious atypia of epidermal cells and by
marked elastosis. In all cases, the PUVA keratoses
could be easily differentiated histopathologically
from psoriasis vulgaris, viral warts, lichenoid kera-
toses, and SCCs.
Gupta et al.4 described the development of dis-
crete, gray-white, asymptomatic keratoses, approx-
imately 4 mm in diameter, in 28 of 52 consecutive
inpatients with psoriasis admitted for treatment with
the modified Goeckerman regimen. Histopathologic
examination of these keratoses differed from PUVA
keratoses in that they usually showed orthokeratotic
hyperkeratosis; parakeratosis was seen occasionally
and papillomatosis was not observed. The dermis
was essentially normal with a mild superficial
perivascular lymphocytic infiltrate in some cases.
The number of patients with nonmelanoma skin
cancer was significantly higher in the PUVA kera-
toses group, äs compared with the number of skin
carcinomas in the large group of psoriasis patients
without these keratoses, who also had received long-
term PUVA treatment. Five years after the Start of
the PUVA treatment 15% of the patients with
PUVA keratoses had developed nonmelanoma skin
cancer; after 8 years this number had increased to
31%. Only 4% of the patients without PUVA kera-
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Fig. 4. PUVA keratosis. Acanthotic epidermis with
parakeratosis and hyperparakeratosis and mild perivas-
cular inflammatory infiltrate. (Hematoxylin-eosin stain;
XI00.)
^%M?l&<*. ••••'^ .NiCsfeS
Fig. 5. Detail of PUVA keratosis: inflammatory infil-
trate slightly invading epidermis. Apoptotic cells in spin-
ous cell layer. (Hematoxylin-eosin stain; X250.)
toses had developed skin cancer 8 years after the
start of the PUVA treatment. Risk factors for the
development of PUVA keratoses were aging, male
sex, and the cumulative dose of UVA. The crude
odds ratio of nonmelanoma skin cancer in the patient
group with PUVA keratoses was 15.2 and the odds
ratio adjusted for the UVA dose and age and sex of
the patient was 6.5. It appeared that SCCs contrib-
uted most to the increased risk of skin cancer. It can
be concluded that PUVA keratoses are associated
with an increased risk of nonmelanoma skin cancer.
Since we started a systematic screening for PUVA
keratoses in 1987, most PUVA keratoses were
detected later than the cutaneous malignancies.
Therefore we have no conclusive evidence yet that
PUVA keratoses are premalignant skin tumors.
Such evidence can only be obtained by prospective
studies in which PUVA-treated psoriasis patients
are observed from the onset of this treatment.
Because the premalignant nature of PUVA kera-
toses could not be excluded, they were removed by
freezing with liquid nitrogen.
Because PUVA keratoses are associated with an
increased risk of nonmelanoma skin cancer, careful
clinical observation of psoriasis patients with PUVA
keratoses is necessary and even cessation of the
PUVA treatment should be considered.
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